Regeneron Pharmaceuticals Inc (REGN)
$773.00 -$0.06 (-0.01%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$85.49B -
Day's Range
$766.86 - $781.32 -
Volume
854,578 -
52 Week Low / High
$735.95 - $1,211.20 -
PE Ratio
19.23x -
PEG Ratio
1.16 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 11
- Strong Buy
- 6
- Buy
- 7
- Hold
- 1
- Sell
- 0
- Strong Sell
- $912.52
- Target Price
Company News
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Regeneron announces three-year data for EYLEA HD Injection 8 mg study — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/regeneron-announces-three-year-data-for-eylea-hd-injection-8-mg-study Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three ...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024
Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat — Oct 25th, 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
-
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom — Oct 31st, 2024
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug. Continue reading View comments...
Portfolio
Comprised of 1 portfolios